CN108295098A - The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application - Google Patents
The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application Download PDFInfo
- Publication number
- CN108295098A CN108295098A CN201810104914.0A CN201810104914A CN108295098A CN 108295098 A CN108295098 A CN 108295098A CN 201810104914 A CN201810104914 A CN 201810104914A CN 108295098 A CN108295098 A CN 108295098A
- Authority
- CN
- China
- Prior art keywords
- unit composition
- symphysis unit
- auxiliary hyperglycemic
- auxiliary
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 230000003345 hyperglycaemic effect Effects 0.000 title claims abstract description 76
- 239000006041 probiotic Substances 0.000 claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 claims abstract description 43
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 41
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 235000013402 health food Nutrition 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 21
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 21
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 21
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 20
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 20
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 20
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 20
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 20
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 20
- 241000031003 Monascus ruber Species 0.000 claims description 19
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 19
- 150000004676 glycans Chemical class 0.000 claims description 19
- 235000013557 nattō Nutrition 0.000 claims description 19
- 229920001282 polysaccharide Polymers 0.000 claims description 18
- 239000005017 polysaccharide Substances 0.000 claims description 18
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 17
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 17
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 17
- 244000068988 Glycine max Species 0.000 claims description 17
- 235000010469 Glycine max Nutrition 0.000 claims description 17
- 229920002752 Konjac Polymers 0.000 claims description 17
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 17
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 17
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 17
- 235000010485 konjac Nutrition 0.000 claims description 17
- 239000000252 konjac Substances 0.000 claims description 17
- 229940006091 aloe polysaccharide Drugs 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 16
- 150000002482 oligosaccharides Chemical class 0.000 claims description 16
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 12
- 244000199866 Lactobacillus casei Species 0.000 claims description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 7
- 229940017800 lactobacillus casei Drugs 0.000 claims description 7
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 5
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims 2
- 241001478240 Coccus Species 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008103 glucose Substances 0.000 abstract description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 244000057717 Streptococcus lactis Species 0.000 description 17
- 235000014897 Streptococcus lactis Nutrition 0.000 description 17
- 241000186605 Lactobacillus paracasei Species 0.000 description 13
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 208000007976 Ketosis Diseases 0.000 description 4
- -1 malt Ketose Chemical class 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of symphysis unit composition of auxiliary hyperglycemic, the symphysis unit composition of the auxiliary hyperglycemic includes prebiotics, probiotics, and weight ratio is 1~10:1~10.The preparation of the symphysis unit composition of the auxiliary hyperglycemic is also disclosed, pharmaceutically acceptable auxiliary material, which is added, in the symphysis unit composition of the auxiliary hyperglycemic is made powder, tablet, granule and capsule.And disclose application of the symphysis unit composition of the auxiliary hyperglycemic in the drug or health food for preparing prevention/auxiliary treatment hyperglycemia diseases.The symphysis unit composition of the present invention is by a variety of probiotics, prebiotics proportioning combination, help to inhibit harmful levels of pathogens breeding, restore gut pH, by stimulating immunity function in enteron aisle, function of intestinal canal is restored normal, it safeguards human body body microecological balance, achievees the effect that reduce blood glucose.
Description
Technical field
The invention belongs to microbe additive technical fields, and in particular to a kind of symphysis unit composition of auxiliary hyperglycemic and
Its preparation and application.
Background technology
Modern society improves with people’s lives level, before the " three high " class disease such as hyperglycemia, hyperlipidemia, hypertension
It is common in the middle-aged and the old, in recent years also continuous rejuvenation, the illness rate of hyperglycemia person's hypertension is twice of non-hyperglycemia person, and companion
There is hyperpietic to be more easy to that myocardial infarction, cerebrovascular accident and peripheral vascular disease occurs, and accelerates retinopathy and renal lesions
Occurrence and development, also studies have shown that the peak of hyperglycemia person's Prevalence of Hypertension occurred than normal person early ten years, serious prestige
Coerce the health of people.Hyperglycemia refers to that blood glucose value is higher than normal range (NR).Studies have shown that cause hyperglycemia major reason it
First, function of intestinal canal is abnormal, it is bad and cause hyperglycemia that intestinal absorption, intestinal flora and enteron aisle influence glycemic control hormone, especially
It is that healthy person intestinal flora has differences with overweight people, diabetes B person's intestinal flora.For this purpose, a kind of energy solution of research and development is above-mentioned
The product of health problem is very important.
Invention content
The first object of the present invention is to provide a kind of symphysis unit composition of auxiliary hyperglycemic；Second is designed to provide
A kind of preparation of the symphysis unit composition of auxiliary hyperglycemic；Third is designed to provide a kind of symphysis unit combination of auxiliary hyperglycemic
The application of object.
The first object of the present invention is achieved in that the symphysis unit composition including the auxiliary hyperglycemic includes benefit
Raw member, probiotics, weight ratio are 1~10：1~10.
The second object of the present invention is achieved in that the preparation of the symphysis unit composition of auxiliary hyperglycemic, and described is auxiliary
It helps in hypoglycemic symphysis unit composition and pharmaceutically acceptable auxiliary material is added powder, tablet, granule, liquid preparation is made
And capsule.
The third object of the present invention is achieved in that the application of the symphysis unit composition of auxiliary hyperglycemic, and described is auxiliary
Help hypoglycemic symphysis unit composition answering in the drug or health food for preparing prevention/auxiliary treatment hyperglycemia diseases
With.
Compared with prior art, the present invention has the following technical effects：
1, symphysis unit composition of the invention is to contribute to a variety of probiotics, prebiotics proportioning combination to inhibit harmful levels of pathogens numerous
It grows, restore gut pH, by stimulating immunity function in enteron aisle, function of intestinal canal is restored normal, safeguards human body body Tiny ecosystem
Balance achievees the effect that reduce blood glucose；
2, symphysis unit composition of the invention can both play the physiological bacterial activity of probiotics, and cooperation prebiotics are again alternative
Ground quickly increases the quantity of probiotics, makes that probiotic action speed is fast and effect is lasting, to play probiotics and prebiotic simultaneously
The physiological function of member；The present invention also has the advantages that significant effect, quick, safe；
3, the present invention obtains the material composition proportioning of science through a large number of experiments, targetedly selects benefit according to application crowd
The optimum composition method of raw bacterium and prebiotics, by scientific and effective proportioning so that the symphysis unit composition plays maximum work(
Effect so that the present invention can not only effectively realize its effect, and selected prebiotics can effective stimulus arranged in pairs or groups it is prebiotic
Bacterium is proliferated, reasonable composition；
4, instructions of taking dosage of the invention is reasonable, and it is indefinite to effectively prevent existing probiotics preparation dosage for obvious effect
It is caused take after to no effect or take the ill effect excessively brought.
Specific implementation mode
With reference to embodiment, the present invention is further illustrated, but is not limited in any way to the present invention,
Based on present invention teach that made by it is any transform or replace, all belong to the scope of protection of the present invention.
The symphysis unit composition of auxiliary hyperglycemic of the present invention includes prebiotics, probiotics, and weight ratio is 1~10：1
~10.
The symphysis unit composition of the auxiliary hyperglycemic includes prebiotics, probiotics, and weight ratio is 3~10：1.
The symphysis unit composition of the auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 1：1~7.
The prebiotics include weight percent composition：Stachyose 0.1~3%, trehalose 1~4%, xylo-oligosaccharide 9
~12%, oligoisomaltose 0.1~3%, oligofructose 5~8%, isomaltoketose 8~11%, chitosan oligosaccharide 0.1~3%,
Soyabean oligosaccharides 3~6%, synanthrin 5~8%, aloe polysaccharide 11~14%, konjac polysaccharide 42~45%.
The prebiotics include weight percent composition：Stachyose 1~2%, trehalose 2~3%, xylo-oligosaccharide 10~
11%, oligoisomaltose 1~2%, oligofructose 6~7%, isomaltoketose 9~10%, chitosan oligosaccharide 1~2%, soybean are low
Glycan 4~5%, synanthrin 6~7%, aloe polysaccharide 12~13%, konjac polysaccharide 43~44%.
The probiotics includes weight percent composition：Lactobacillus casei 10~25%, Lactobacillus rhamnosus 30~
40%, lactobacillus plantarum 5~15%, bafillus natto 0~15%, bifidobacterium infantis 3~7%, bifidobacterium longum 3~
7%, bifidobacterium bifidum 3~7%, Lactococcus lactis 0~7%, monascus ruber 0~15%.
The probiotics includes weight percent composition：Lactobacillus casei 10~20%, Lactobacillus rhamnosus 30~
40%, lactobacillus plantarum 5~15%, bafillus natto 5~15%, bifidobacterium infantis 3~7%, bifidobacterium longum 3~
7%, bifidobacterium bifidum 3~7%, Lactococcus lactis 3~7%, monascus ruber 5~15%.
The probiotics includes weight percent composition：Lactobacillus casei 13~17%, Lactobacillus rhamnosus 33~
37%, lactobacillus plantarum 8~12%, bafillus natto 8~12%, bifidobacterium infantis 4~6%, bifidobacterium longum 4~
6%, bifidobacterium bifidum 4~6%, Lactococcus lactis 4~6%, monascus ruber 8~12%.
Pharmaceutically acceptable auxiliary material is added in the symphysis unit composition of the auxiliary hyperglycemic, powder, piece is made
Agent, granule, liquid preparation and capsule.
The symphysis unit composition of the auxiliary hyperglycemic prepare prevention/auxiliary treatment hyperglycemia diseases drug or
Application in health food.
The symphysis unit composition instructions of taking of the auxiliary hyperglycemic is 1~2 time on the one, every time 10~20g.
The entitled L.casei of Latin of the Lactobacillus casei.
The entitled L.rhamnosus of Latin of the Lactobacillus rhamnosus.
The entitled L.plantarum of Latin of the lactobacillus plantarum.
The entitled B.natto of Latin of the bafillus natto.
The entitled Bifidobacterium infantisy of Latin of the bifidobacterium infantis.
The entitled B.longum of Latin of the bifidobacterium longum.
The entitled B.bifidum of Latin of the bifidobacterium bifidum.
The entitled Lactococus lactis of Latin of the Lactococcus lactis.
The entitled Monascuspurpureus of Latin of the monascus ruber.
Embodiment 1
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 1:10.
Embodiment 2
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 10:1.
Embodiment 3
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 9:2.
Embodiment 4
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 2:9.
Embodiment 5
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 7.5:3.
Embodiment 6
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 3:7.5.
Embodiment 7
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 5:4.
Embodiment 8
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 3:1.
Embodiment 9
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 1:7.
Embodiment 10
The symphysis unit composition of auxiliary hyperglycemic includes prebiotics, probiotics, weight ratio 1:1.
Embodiment 11
The symphysis unit composition of auxiliary hyperglycemic as described in Example 1, the prebiotics include weight percent composition：Water
Threose 0.1%, trehalose 1%, xylo-oligosaccharide 9%, oligoisomaltose 0.1%, oligofructose 5%, isomaltoketose 11%,
Chitosan oligosaccharide 0.8%, soyabean oligosaccharides 6%, synanthrin 8%, aloe polysaccharide 14%, konjac polysaccharide 45%.
Embodiment 12
The symphysis unit composition of auxiliary hyperglycemic as described in Example 2, the prebiotics include weight percent composition：Water
Threose 3%, trehalose 4%, xylo-oligosaccharide 12%, oligoisomaltose 3%, oligofructose 8%, isomaltoketose 8%, shell are few
Sugar 1%, soyabean oligosaccharides 3%, synanthrin 5%, aloe polysaccharide 11%, konjac polysaccharide 42%.
Embodiment 13
The symphysis unit composition of auxiliary hyperglycemic as described in Example 3, the prebiotics include weight percent composition：Water
Threose 2.35%, trehalose 2.5%, xylo-oligosaccharide 10.5%, oligoisomaltose 1.55%, oligofructose 6.5%, different malt
Ketose 9.5%, chitosan oligosaccharide 0.1%, soyabean oligosaccharides 4.5%, synanthrin 6.5%, aloe polysaccharide 12.5%, konjac polysaccharide
43.5%.
Embodiment 14
The symphysis unit composition of auxiliary hyperglycemic as described in Example 4, the prebiotics include weight percent composition：Water
Threose 1%, trehalose 2%, xylo-oligosaccharide 10%, oligoisomaltose 1%, oligofructose 6%, isomaltoketose 9%, shell are few
Sugar 2%, soyabean oligosaccharides 5%, synanthrin 7%, aloe polysaccharide 13%, konjac polysaccharide 44%.
Embodiment 15
The symphysis unit composition of auxiliary hyperglycemic as described in Example 5, the prebiotics include weight percent composition：Water
Threose 2%, trehalose 3%, xylo-oligosaccharide 11%, oligoisomaltose 2%, oligofructose 7%, isomaltoketose 9%, shell are few
Sugar 1%, soyabean oligosaccharides 4%, synanthrin 6%, aloe polysaccharide 12%, konjac polysaccharide 43%.
Embodiment 16
The symphysis unit composition of auxiliary hyperglycemic as described in Example 6, the prebiotics include weight percent composition：Water
Threose 3%, trehalose 4%, xylo-oligosaccharide 12%, oligoisomaltose 3%, oligofructose 8%, isomaltoketose 8%, shell are few
Sugar 1%, soyabean oligosaccharides 3%, synanthrin 5%, aloe polysaccharide 11%, konjac polysaccharide 42%.
Embodiment 17
The symphysis unit composition of auxiliary hyperglycemic as described in Example 7, the prebiotics include weight percent composition：Water
Threose 0.1%, trehalose 1%, xylo-oligosaccharide 9%, oligoisomaltose 0.1%, oligofructose 5%, isomaltoketose 11%,
Chitosan oligosaccharide 0.8%, soyabean oligosaccharides 6%, synanthrin 8%, aloe polysaccharide 14%, konjac polysaccharide 45%.
Embodiment 18
The symphysis unit composition of auxiliary hyperglycemic as described in Example 8, the prebiotics include weight percent composition：Water
Threose 0.45%, trehalose 1.5%, xylo-oligosaccharide 10.5%, oligoisomaltose 1.55%, oligofructose 6.5%, different malt
Ketose 9.5%, chitosan oligosaccharide 3%, soyabean oligosaccharides 4.5%, synanthrin 6.5%, aloe polysaccharide 12.5%, konjac polysaccharide 43.5%.
Embodiment 19
The symphysis unit composition of auxiliary hyperglycemic as described in Example 9, the prebiotics include weight percent composition：Water
Threose 2%, trehalose 3%, xylo-oligosaccharide 11%, oligoisomaltose 2%, oligofructose 7%, isomaltoketose 9%, shell are few
Sugar 1%, soyabean oligosaccharides 4%, synanthrin 6%, aloe polysaccharide 12%, konjac polysaccharide 43%.
Embodiment 20
The symphysis unit composition of auxiliary hyperglycemic as described in Example 10, the prebiotics include weight percent composition：
Stachyose 1%, trehalose 2%, xylo-oligosaccharide 10%, oligoisomaltose 1%, oligofructose 6%, isomaltoketose 10%,
Chitosan oligosaccharide 1%, soyabean oligosaccharides 5%, synanthrin 7%, aloe polysaccharide 13%, konjac polysaccharide 44%.
Embodiment 21
The symphysis unit composition of auxiliary hyperglycemic as described in Example 1, the prebiotics include weight percent composition：Water
Threose 1%, trehalose 2%, xylo-oligosaccharide 10.5%, oligoisomaltose 1.5%, oligofructose 6.5%, isomaltoketose
9.5%, chitosan oligosaccharide 2%, soyabean oligosaccharides 4.5%, synanthrin 6.5%, aloe polysaccharide 12.5%, konjac polysaccharide 43.5%.
Embodiment 22
The symphysis unit composition of auxiliary hyperglycemic as described in Example 2, the prebiotics include weight percent composition：Water
Threose 1.55%, trehalose 2.5%, xylo-oligosaccharide 10.5%, oligoisomaltose 1.55%, oligofructose 6.5%, different malt
Ketose 9.5%, chitosan oligosaccharide 0.9%, soyabean oligosaccharides 4.5%, synanthrin 6.5%, aloe polysaccharide 12.5%, konjac polysaccharide
43.5%.
Embodiment 23
The symphysis unit composition of auxiliary hyperglycemic as described in Example 3, the prebiotics include weight percent composition：Water
Threose 0.9%, trehalose 2.5%, xylo-oligosaccharide 10.5%, oligoisomaltose 1.55%, oligofructose 6.5%, different malt
Ketose 9.5%, chitosan oligosaccharide 1.55%, soyabean oligosaccharides 4.5%, synanthrin 6.5%, aloe polysaccharide 12.5%, konjac polysaccharide
43.5%.
Embodiment 24
The symphysis unit composition of auxiliary hyperglycemic as described in Example 4, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 17%, Lactobacillus rhamnosus 30%, lactobacillus plantarum 5%, bafillus natto 5%, bifidobacterium infantis 7%,
Bifidobacterium longum 7%, bifidobacterium bifidum 7%, Lactococcus lactis 7%, monascus ruber 15%.
Embodiment 25
The symphysis unit composition of auxiliary hyperglycemic as described in Example 5, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 10%, Lactobacillus rhamnosus 40%, lactobacillus plantarum 10%, bafillus natto 10%, bifidobacterium infantis
5%, bifidobacterium longum 5%, bifidobacterium bifidum 5%, Lactococcus lactis 5%, monascus ruber 10%.
Embodiment 26
The symphysis unit composition of auxiliary hyperglycemic as described in Example 6, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 13%, Lactobacillus rhamnosus 40%, lactobacillus plantarum 15%, bafillus natto 15%, bifidobacterium infantis
3%, bifidobacterium longum 3%, bifidobacterium bifidum 3%, Lactococcus lactis 3%, monascus ruber 5%.
Embodiment 27
The symphysis unit composition of auxiliary hyperglycemic as described in Example 7, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 15%, Lactobacillus rhamnosus 33%, lactobacillus plantarum 8%, bafillus natto 8%, bifidobacterium infantis 6%,
Bifidobacterium longum 6%, bifidobacterium bifidum 6%, Lactococcus lactis 6%, monascus ruber 12%.
Embodiment 28
The symphysis unit composition of auxiliary hyperglycemic as described in Example 8, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 13%, Lactobacillus rhamnosus 37%, lactobacillus plantarum 10%, bafillus natto 10%, bifidobacterium infantis
5%, bifidobacterium longum 5%, bifidobacterium bifidum 5%, Lactococcus lactis 5%, monascus ruber 10%.
Embodiment 29
The symphysis unit composition of auxiliary hyperglycemic as described in Example 9, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 15%, Lactobacillus rhamnosus 37%, lactobacillus plantarum 12%, bafillus natto 12%, bifidobacterium infantis
4%, bifidobacterium longum 4%, bifidobacterium bifidum 4%, Lactococcus lactis 4%, monascus ruber 8%.
Embodiment 30
The symphysis unit composition of auxiliary hyperglycemic as described in Example 10, the probiotics includes weight percent composition：
Lactobacillus casei 13%, Lactobacillus rhamnosus 40%, lactobacillus plantarum 15%, bafillus natto 15%, bifidobacterium infantis
3%, bifidobacterium longum 3%, bifidobacterium bifidum 3%, Lactococcus lactis 3%, monascus ruber 5%.
Embodiment 31
The symphysis unit composition of auxiliary hyperglycemic as described in Example 1, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 20%, Lactobacillus rhamnosus 30%, lactobacillus plantarum 10%, bafillus natto 10%, bifidobacterium infantis
5%, bifidobacterium longum 5%, bifidobacterium bifidum 5%, Lactococcus lactis 5%, monascus ruber 10%.
Embodiment 32
The symphysis unit composition of auxiliary hyperglycemic as described in Example 2, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 17%, Lactobacillus rhamnosus 30%, lactobacillus plantarum 5%, bafillus natto 5%, bifidobacterium infantis 7%,
Bifidobacterium longum 7%, bifidobacterium bifidum 7%, Lactococcus lactis 7%, monascus ruber 15%.
Embodiment 33
The symphysis unit composition of auxiliary hyperglycemic as described in Example 3, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 15%, Lactobacillus rhamnosus 37%, lactobacillus plantarum 12%, bafillus natto 12%, bifidobacterium infantis
4%, bifidobacterium longum 4%, bifidobacterium bifidum 4%, Lactococcus lactis 4%, monascus ruber 8%.
Embodiment 34
The symphysis unit composition of auxiliary hyperglycemic as described in Example 4, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 17%, Lactobacillus rhamnosus 33%, lactobacillus plantarum 10%, bafillus natto 10%, bifidobacterium infantis
5%, bifidobacterium longum 5%, bifidobacterium bifidum 5%, Lactococcus lactis 5%, monascus ruber 10%.
Embodiment 35
The symphysis unit composition of auxiliary hyperglycemic as described in Example 5, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 15%, Lactobacillus rhamnosus 33%, lactobacillus plantarum 8%, bafillus natto 8%, bifidobacterium infantis 6%,
Bifidobacterium longum 6%, bifidobacterium bifidum 6%, Lactococcus lactis 6%, monascus ruber 12%.
Embodiment 36
The symphysis unit composition of auxiliary hyperglycemic as described in Example 6, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 15%, Lactobacillus rhamnosus 35%, lactobacillus plantarum 10%, bafillus natto 10%, bifidobacterium infantis
5%, bifidobacterium longum 5%, bifidobacterium bifidum 5%, Lactococcus lactis 5%, monascus ruber 10%.
Embodiment 37
The symphysis unit composition of auxiliary hyperglycemic as described in Example 7, the probiotics includes weight percent composition：It is dry
Lactobacillus paracasei 25%, Lactobacillus rhamnosus 40%, lactobacillus plantarum 14%, bifidobacterium infantis 7%, bifidobacterium longum 7%, two
Discrimination Bifidobacterium 7%.
Embodiment 38
A kind of preparation of the symphysis unit composition of auxiliary hyperglycemic, the preparation are to be combined in symphysis unit described in embodiment 1
Pharmaceutically acceptable auxiliary material is added in object, powder is made.
Embodiment 39
A kind of preparation of the symphysis unit composition of auxiliary hyperglycemic, the preparation are to be combined in symphysis unit described in embodiment 3
Pharmaceutically acceptable auxiliary material is added in object, tablet is made.
Embodiment 40
A kind of preparation of the symphysis unit composition of auxiliary hyperglycemic, the preparation are the symphysis unit combination described in embodiment 5
Pharmaceutically acceptable auxiliary material is added in object, granule is made.
Embodiment 41
A kind of preparation of the symphysis unit composition of auxiliary hyperglycemic, the preparation are the symphysis unit combination described in embodiment 7
Pharmaceutically acceptable auxiliary material is added in object, liquid preparation is made.
Embodiment 42
A kind of preparation of the symphysis unit composition of auxiliary hyperglycemic, the preparation are the symphysis unit combination described in embodiment 9
Pharmaceutically acceptable auxiliary material is added in object, capsule is made.
Case 1
Zhang, man, Zhaotong County, Yunnan people, 56 years old, symptom high blood glucose took symphysis unit composition capsule preparation of the present invention, one day 1
Secondary, each 20g, after being used continuously 15 days, blood glucose value is substantially reduced.
Case 2
Mr. Wang, female, Kunming, Yunnan people, 46 years old, symptom high blood glucose took symphysis unit composition capsule preparation of the present invention, and one
It 1 time, each 20g, after being used continuously 20 days, blood glucose value is substantially reduced.
Case 3
Zhao so-and-so, female, Kunming, Yunnan people, 62 years old, symptom high blood glucose took symphysis unit composition capsule preparation of the present invention, one
It 2 times, each 10g, after being used continuously 15 days, blood glucose value is substantially reduced.
Claims (9)
1. a kind of symphysis unit composition of auxiliary hyperglycemic, it is characterised in that the symphysis unit composition packet of the auxiliary hyperglycemic
Prebiotics, probiotics are included, weight ratio is 1~10：1~10.
2. the symphysis unit composition of auxiliary hyperglycemic according to claim 1, it is characterised in that the auxiliary hyperglycemic
Symphysis unit composition include prebiotics, probiotics, weight ratio is 3~10：1.
3. the symphysis unit composition of auxiliary hyperglycemic according to claim 1, it is characterised in that the auxiliary hyperglycemic
Symphysis unit composition include prebiotics, probiotics, weight ratio 1：1~7.
4. the symphysis unit composition of auxiliary hyperglycemic according to claim 1, it is characterised in that the prebiotics include
Weight percent composition：Stachyose 0.1~3%, trehalose 1~4%, xylo-oligosaccharide 9~12%, oligoisomaltose 0.1~
3%, oligofructose 5~8%, isomaltoketose 8~11%, chitosan oligosaccharide 0.1~3%, soyabean oligosaccharides 3~6%, synanthrin 5~
8%, aloe polysaccharide 11~14%, konjac polysaccharide 42~45%.
5. the symphysis unit composition of auxiliary hyperglycemic according to claim 1, it is characterised in that the prebiotics include
Weight percent composition：Stachyose 1~2%, trehalose 2~3%, xylo-oligosaccharide 10~11%, oligoisomaltose 1~2%,
Oligofructose 6~7%, isomaltoketose 9~10%, chitosan oligosaccharide 1~2%, soyabean oligosaccharides 4~5%, synanthrin 6~7%, reed
Luxuriant growth polysaccharide 12~13%, konjac polysaccharide 43~44%.
6. the symphysis unit composition of auxiliary hyperglycemic according to claim 1, it is characterised in that the probiotics includes
Weight percent composition：Lactobacillus casei 10~25%, Lactobacillus rhamnosus 30~40%, lactobacillus plantarum 5~15%, natto
Bacillus 0~15%, bifidobacterium infantis 3~7%, bifidobacterium longum 3~7%, bifidobacterium bifidum 3~7%, lactic acid breast
Coccus 0~7%, monascus ruber 0~15%.
7. the symphysis unit composition of auxiliary hyperglycemic according to claim 1, it is characterised in that the probiotics includes
Weight percent composition：Lactobacillus casei 13~17%, Lactobacillus rhamnosus 33~37%, lactobacillus plantarum 8~12%, natto
Bacillus 8~12%, bifidobacterium infantis 4~6%, bifidobacterium longum 4~6%, bifidobacterium bifidum 4~6%, lactic acid breast
Coccus 4~6%, monascus ruber 8~12%.
8. a kind of preparation of the symphysis unit composition of auxiliary hyperglycemic as described in claim 1~7 is any, it is characterised in that institute
Pharmaceutically acceptable auxiliary material is added in the symphysis unit composition for the auxiliary hyperglycemic stated, powder, tablet, granule, liquid is made
Body preparation and capsule.
9. a kind of application of the symphysis unit composition of auxiliary hyperglycemic as described in claim 1~7 is any, it is characterised in that institute
The symphysis unit composition for the auxiliary hyperglycemic stated is in the drug or health food for preparing prevention/auxiliary treatment hyperglycemia diseases
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810104914.0A CN108295098A (en) | 2018-02-02 | 2018-02-02 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810104914.0A CN108295098A (en) | 2018-02-02 | 2018-02-02 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108295098A true CN108295098A (en) | 2018-07-20 |
Family
ID=62864242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810104914.0A Pending CN108295098A (en) | 2018-02-02 | 2018-02-02 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108295098A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741091A (en) * | 2018-08-29 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food for adjusting infantile enteritis immune response |
| CN109055278A (en) * | 2018-09-17 | 2018-12-21 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
| CN109221519A (en) * | 2018-09-25 | 2019-01-18 | 西安源森生物科技有限公司 | A kind of hypoglycemic oligosaccharide probiotics solid beverage and preparation method thereof |
| CN109481510A (en) * | 2018-10-11 | 2019-03-19 | 张军毅 | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof |
| CN111000106A (en) * | 2019-12-27 | 2020-04-14 | 刘俊 | Composite probiotic solid beverage |
| CN112662717A (en) * | 2021-01-28 | 2021-04-16 | 华南理工大学 | Lactobacillus rhamnosus exopolysaccharide and preparation method and application thereof |
| US11291697B2 (en) | 2019-02-20 | 2022-04-05 | Infinitus (China) Company Ltd. | Probiotic composition and use thereof |
| US11446342B2 (en) | 2019-02-20 | 2022-09-20 | Infinitus (China) Company Ltd. | Composite probiotics and use thereof |
| CN115137757A (en) * | 2022-07-29 | 2022-10-04 | 承葛健康科技(广东)有限公司 | Probiotic composition assisting in reducing blood sugar |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080107634A1 (en) * | 2004-11-16 | 2008-05-08 | Anidral S.R.L. | Probiotic Bacteria Based Composition and Use Thereof in the Prevention and/or Treatment of Respiratory Pathologies and/or Infections and in the Improvement of the Intestinal Functionality |
| CN101810222A (en) * | 2010-04-23 | 2010-08-25 | 陕西农产品加工技术研究院 | Synbiotic goat milk powder |
| CN104381694A (en) * | 2014-11-29 | 2015-03-04 | 郑州后羿制药有限公司 | Composite microecological preparation |
| CN104740138A (en) * | 2013-12-31 | 2015-07-01 | 深圳华大基因科技有限公司 | Composition containing aloe, probiotics and prebiotics and application of composition |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
-
2018
- 2018-02-02 CN CN201810104914.0A patent/CN108295098A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080107634A1 (en) * | 2004-11-16 | 2008-05-08 | Anidral S.R.L. | Probiotic Bacteria Based Composition and Use Thereof in the Prevention and/or Treatment of Respiratory Pathologies and/or Infections and in the Improvement of the Intestinal Functionality |
| CN101810222A (en) * | 2010-04-23 | 2010-08-25 | 陕西农产品加工技术研究院 | Synbiotic goat milk powder |
| CN104740138A (en) * | 2013-12-31 | 2015-07-01 | 深圳华大基因科技有限公司 | Composition containing aloe, probiotics and prebiotics and application of composition |
| CN104381694A (en) * | 2014-11-29 | 2015-03-04 | 郑州后羿制药有限公司 | Composite microecological preparation |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
Non-Patent Citations (2)
| Title |
|---|
| ALSHERAJI S H等: "Prebiotics as functional foods:A review", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| 周景欣等: "几种益生元制剂对肠道菌群作用效果的研究", 《中国微生态学杂志》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741091A (en) * | 2018-08-29 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food for adjusting infantile enteritis immune response |
| CN109055278A (en) * | 2018-09-17 | 2018-12-21 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
| CN109055278B (en) * | 2018-09-17 | 2019-09-06 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
| CN109221519A (en) * | 2018-09-25 | 2019-01-18 | 西安源森生物科技有限公司 | A kind of hypoglycemic oligosaccharide probiotics solid beverage and preparation method thereof |
| CN109481510A (en) * | 2018-10-11 | 2019-03-19 | 张军毅 | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof |
| US11291697B2 (en) | 2019-02-20 | 2022-04-05 | Infinitus (China) Company Ltd. | Probiotic composition and use thereof |
| US11446342B2 (en) | 2019-02-20 | 2022-09-20 | Infinitus (China) Company Ltd. | Composite probiotics and use thereof |
| CN111000106A (en) * | 2019-12-27 | 2020-04-14 | 刘俊 | Composite probiotic solid beverage |
| CN112662717A (en) * | 2021-01-28 | 2021-04-16 | 华南理工大学 | Lactobacillus rhamnosus exopolysaccharide and preparation method and application thereof |
| CN115137757A (en) * | 2022-07-29 | 2022-10-04 | 承葛健康科技(广东)有限公司 | Probiotic composition assisting in reducing blood sugar |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108295098A (en) | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application | |
| CN108576822A (en) | A kind of symphysis unit composition and its preparation and application with strengthen immunity function | |
| EP2766026B1 (en) | Prevention and diagnosis of visceral fat | |
| CN108541951A (en) | A kind of symphysis unit composition and its preparation for preventing senile dementia, enhancing memory | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| RU2013137404A (en) | BIFIDOBACTERIUM BIFIDUM STRAINS FOR USE IN DISEASES OF THE GASTROINTESTINAL TRACT | |
| JP2012520325A5 (en) | ||
| CN109619540A (en) | A kind of probiotic composition and its preparation method and application with functions of loosening bowel relieving constipation | |
| US20200030395A1 (en) | Probiotics composition containing hericium erinaceus | |
| CN107095292A (en) | It is a kind of that there is plant composite enzyme of regulation gut flora function and preparation method thereof | |
| CN108576823A (en) | A kind of anti-oxidant, anti-aging symphysis unit composition and its preparation and application | |
| US20160089404A1 (en) | Lachnospiraceae in the gut microbiota and association with body weight | |
| CN106727725A (en) | A kind of probiotics capsulae enterosolubilis and its utricule for treating enteric flora disturbance | |
| JP6989154B2 (en) | Colon target composition of biologically active ingredient, and its utilization | |
| CN108378370A (en) | A kind of symphysis unit composition and its preparation and application | |
| CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
| CN111343972A (en) | Oral pharmaceutical formulations comprising bacteria | |
| CN108244655A (en) | A kind of tranquilizing the mind, antidepressant symphysis unit composition and its preparation and application | |
| CN108514121A (en) | A kind of defaecation, the symphysis unit composition of toxin expelling and its preparation and application | |
| CN109718289A (en) | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases | |
| CN108567801B (en) | Oral rehydration salt and preparation method and application thereof | |
| CN106265876A (en) | A kind of probiotic composition and the application in alleviation or treatment constipation thereof | |
| CN112515171A (en) | Fluid-supplementing probiotic composition and application thereof | |
| CN102106925B (en) | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator | |
| CN106798755B (en) | Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180720 |
|
| WD01 | Invention patent application deemed withdrawn after publication |